Trials / Recruiting
RecruitingNCT06593522
A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Anvumetostat in Subjects With Methylthioadenosine Phosphorylase (MTAP)-Deleted Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The main objective of the study is to characterize safety and efficacy of 2 dose levels of anvumetostat by investigator, and to evaluate anvumetostat monotherapy efficacy by Blinded Independent Central Review (BICR).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | anvumetostat | Film-coated tablet |
Timeline
- Start date
- 2024-12-26
- Primary completion
- 2028-11-29
- Completion
- 2030-11-29
- First posted
- 2024-09-19
- Last updated
- 2026-04-07
Locations
91 sites across 16 countries: United States, Australia, Brazil, Canada, China, Czechia, Hong Kong, Japan, Latvia, Netherlands, Portugal, Singapore, South Korea, Switzerland, Taiwan, Turkey (Türkiye)
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06593522. Inclusion in this directory is not an endorsement.